- Introduction
- Scope and objectives
- Methodology
- Classification of prostate cancer
- Localised prostate cancer
- Locally advanced prostate cancer
- Prostate cancer in PSA relapse
- Disseminated prostate cancer
- Dissemination and implementation
- Recommendations for future research
- Appendices
- Bibliography
- Full list of tables and figures
This section is a compilation of the different future research recommendations proposed throughout this guide.
| A | Randomised trials should be started comparing cryotherapy and high intensity focused ultrasound with standard treatments in patients with clinically localised prostate cancer. |
| √ | Randomised trials should be started to assess the usefulness of modified fragmentations (hypofragmentation, etc) of radiotherapy for prostate cancer. |
| A | Randomised trials should be started comparing cryotherapy and high intensity focused ultrasound with standard treatments in patients with prostate cancer at a locally advanced clinical stage. |
| √ | Randomised trials should be started to assess the usefulness of docetaxel administered as a concomitant or adjuvant to radiotherapy after local treatment. |
| √ | Randomised trials should be started to determine the appropriate hormone treatment (monotherapy with antiandrogens, monotherapy with LHRH agonists or complete androgen blockade) in prostate cancer patients at the locally advanced clinical stage. |
| D | Clinical trials should be launched to evaluate local salvage therapies in terms of survival and quality of life in men with biochemical recurrence after radiotherapy or brachytherapy. |
| √ | Patients with androgen-independent disseminated prostate cancer (those for whom androgen suppression and complete androgen blockade have failed) should be offered inclusion in clinical trials to evaluate the efficacy and safety of second-line hormone therapy, comparing it with chemotherapy that has proven effective. |
| √ | Patients with PSA relapse, androgen-independence, who are asymptomatic and without documented metastatic disease should be offered inclusion in clinical trials that compare early and delayed start chemotherapy. |
| √ | Patients with androgen-independent disseminated prostate cancer for whom chemotherapy treatment has been decided, should be offered inclusion in clinical trials to compare the safety and efficacy of chemotherapy with chemotherapy associated with LHRH agonists. |
Latest update: May 2009
